Noveris Health Sciences Inc.
Other OTCTotal Valuation
Noveris Health Sciences Inc. carries a market capitalization of 64.40M, placing it among publicly traded companies globally. Its enterprise value stands at 46.66M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 64.40M |
| Enterprise Value | 46.66M |
Share Statistics
Noveris Health Sciences Inc. currently has 58.55M shares outstanding.
| Shares Outstanding | 58.55M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Noveris Health Sciences Inc. trades at a trailing price-to-earnings ratio of 30.10.
| PE Ratio | 30.10 |
| PS Ratio | N/A |
| PB Ratio | -2.63 |
| P/TBV Ratio | -21.41 |
| P/FCF Ratio | -170.00 |
| P/OCF Ratio | -170.00 |
Enterprise Valuation
On an enterprise value basis, Noveris Health Sciences Inc. trades at an EV/EBITDA multiple of 4.64 and an EV/FCF ratio of 31.00.
| EV / Sales | N/A |
| EV / EBITDA | 4.64 |
| EV / EBIT | 4.64 |
| EV / FCF | 31.00 |
Financial Position
Noveris Health Sciences Inc. maintains a current ratio of 0.48, meaning it holds 0.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -18.82, indicating conservative leverage, while an interest coverage ratio of -2.77 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.48 |
| Quick Ratio | 0.47 |
| Debt / Equity | -18.82 |
| Debt / EBITDA | -0.85 |
| Interest Coverage | -2.77 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | 155.47 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | -8.25 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Noveris Health Sciences Inc.'s stock has gained approximately 157042.85714% over the past 52 weeks. The 50-day moving average sits at 1.50, while the 200-day moving average is 0.68.
| Beta (5Y) | N/A |
| 52-Week Price Change | 157042.85714% |
| 50-Day Moving Average | 1.50 |
| 200-Day Moving Average | 0.68 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -496,235.00, while operating income came in at -496,235.00.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -496,235.00 |
| Pretax Income | 1.60M |
| Net Income | 1.60M |
| EBITDA | -496,235.00 |
| EBIT | -496,235.00 |
| Earnings Per Share (EPS) | 0.06 |
Balance Sheet
Noveris Health Sciences Inc. holds 2.03M in cash and equivalents against 424,269.00 in total debt, resulting in a net debt position of -1.61M. Total book value stands at -18.37M, with working capital of -2.25M providing operational flexibility.
| Cash & Cash Equivalents | 2.03M |
| Total Debt | 424,269.00 |
| Net Debt | -1.61M |
| Equity (Book Value) | -18.37M |
| Book Value Per Share | -0.70 |
| Working Capital | -2.25M |
Cash Flow
Noveris Health Sciences Inc. produced -283,922.00 in operating cash flow over the past twelve months.
| Operating Cash Flow | -283,922.00 |
| Capital Expenditures | N/A |
| Free Cash Flow | -283,922.00 |
| FCF Per Share | -0.01 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -4.78 |
| FCF Yield | -0.59 |
Stock Splits
Noveris Health Sciences Inc.'s most recent stock split took place on April 21, 2022 with a 50:1 split ratio.
| Last Split Date | 4/21/2022 |
| Split Ratio | 50:1 |
Scores
Noveris Health Sciences Inc. posts an Altman Z-Score of -102.10, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -102.10 |